A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA

Takahiro Nonaka¹, Toshihiko Yamada¹, Tatsuhiro Ishimura¹, Daiying Zuo², John R Moffett³, Joseph H Neale⁴ and Tatsuo Yamamoto¹

Abstract
N-acetylaspartylglutamate (NAAG) is the third most prevalent and widely distributed neurotransmitter in the mammalian nervous system. NAAG activates a group II metabotropic glutamate receptor (mGluR3) and is inactivated by an extracellular enzyme, glutamate carboxypeptidase II (GCPII) in vivo. Inhibitors of this enzyme are analgesic in animal models of inflammatory, neuropathic and bone cancer pain. NAAG and GCPII are present in the locus coeruleus, a center for the descending noradrenergic inhibitory pain system. In the formalin footpad model, systemic treatment with GCPII inhibitors reduces both phases of the inflammatory pain response and increases release of spinal noradrenaline. This analgesic efficacy is blocked by systemic injection of a group II mGluR antagonist, by intrathecal (spinal) injection of an alpha 2 adrenergic receptor antagonist and by microinjection of an a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist directly into the contralateral locus coeruleus. Footpad inflammation increases release of glutamate in the contralateral locus coeruleus and systemic treatment with a GCPII inhibitor blocks this increase. Direct injection of GCPII inhibitors into the contralateral or ipsilateral locus coeruleus reduces both phases of the inflammatory pain response in a dose-dependent manner and the contralateral effect also is blocked by intrathecal injection of an alpha 2 adrenergic receptor antagonist. These data support the hypothesis that the analgesic efficacy of systemically administered GCPII inhibitors is mediated, at least in part, by the contralateral locus coeruleus via group II mGluR, AMPA and alpha 2 adrenergic receptors.

Keywords
N-acetylaspartylglutamate, glutamate carboxypeptidase II, inflammatory pain, locus coeruleus, metabotropic glutamate receptor, N-methyl-D-aspartate receptor

Date received: 6 July 2016; revised: 24 January 2017; accepted: 31 January 2017

Introduction
N-acetylaspartylglutamate (NAAG) is the most prevalent peptide co-transmitter in the mammalian nervous system.¹² NAAG is inactivated by an extracellular glial peptidase, glutamate carboxypeptidase II (GCPII). Inhibitors of GCPII elevate synaptic levels of NAAG³⁴ resulting in NAAG activation of presynaptic type 3 metabotropic glutamate receptors (mGluR3)⁵ and the inhibition of transmitter release.³⁴⁵ NAAG also has been found to act as an antagonist at N-methyl-D-aspartate (NMDA) receptors⁹ that contain NR2A and 2B subunits but not other NMDA receptors.¹⁰¹¹

¹Department of Anesthesiology, School of Medical Science, Kumamoto University, Kumamoto, Japan
²Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China
³Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
⁴Department of Biology, Georgetown University, Washington, DC, USA

Corresponding author:
Tatsu Yamamoto, Department of Anesthesiology, School of Medical Science, Kumamoto University, I-1-1-1 Honjo, Chuo-ku, Kumamoto-shi, Kumamoto 860-8556, Japan.
Email: yamamot@kumamoto-u.ac.jp

Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Inhibitors of GCPII and GCPII knock-out mice have been studied in several animal models of clinical disorders\textsuperscript{12–16} leading to the hypothesis that activation of group II metabotropic glutamate receptors by elevated levels of NAAG has clinical potential. In the present paper, we further test this hypothesis in an animal model of inflammatory pain.

We previously reported that systemic, intrathecal and intracerebroventricular injection of NAAG peptidase inhibitors produced a group II mGluR-dependent analgesic effect in various rat pain models, such as inflammatory, neuropathic and bone cancer pain models by inhibition of GCPII.\textsuperscript{4,17–21} Microinjection of a GCPII inhibitor into either the PAG or RVM, important nuclei in the descending pain pathway, produced an analgesic effect in the rat formalin model of inflammatory pain.\textsuperscript{22} Similarly, the locus coeruleus (LC) is a key nucleus of the descending pain inhibitory system. NAAG, mGluR3 and GCPII are expressed in LC.\textsuperscript{23–25} It has been reported that, in LC, glutamate stimulates noradrenaline release in the spinal cord by an activation of LC \(\alpha\)-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors.\textsuperscript{26,27}

In the present study, the role of the LC and the descending noradrenergic pathway in the analgesic efficacy of GCPII inhibition were examined in the rat formalin model of inflammatory pain (Table 1).

**Material and methods**

This research was performed according to a protocol approved by the Institutional Animal Care Committee of Kumamoto University. Male Sprague–Dawley rats (250–300 g; Japan SLC, Inc., Shizuoka, Japan) were housed in groups of two, maintained on a 12-h dark–light cycle, and permitted food and water ad libitum. Animals were handled on arrival and housed for at least three days before testing. Animals were euthanized immediately after behavioral or microdialysis studies.

**Drugs**

The GCPII inhibitors \((S)-2-\{3-[\{(S)-1-carboxy-3-methylbutyl]ureido\}pentanedioic acid (ZJ43, molecular weight = 304.3)\textsuperscript{28} and 2-(phosphonomethyl) pentanedioic acid (2-PMPA, molecular weight = 314)\textsuperscript{29} were from Reagents4Research LLC (Hangzhou, CN). The group II metabotropic glutamate receptor (mGluR2/3) antagonist, LY341495,\textsuperscript{30} was from Tocris Cookson Ltd (Bristol, UK). The alpha 2 adrenergic receptor antagonist, idazoxan, and the AMPA receptor antagonist, 6-cyano-7-nitroquinoxaline (CNQX), were from Sigma (St. Louis, MO).

**LC cannulae placement for microinjection**

Implantation of the injection cannulae into the LC was performed under halothane anesthesia. Rats were placed in a stereotaxic apparatus and stainless steel 26G thin wall guide cannulae (C315G, Plastics One, VA) were stereotaxically placed at the level of the ipsilateral or contralateral LC through a burr hole.

| Table 1. IP NAAG peptidase inhibitor delivery studies (a) and contralateral and ipsilateral NAAG peptidase inhibitor delivery studies (b). |
| --- |
| (a) |
| 1. IP 2-PMPA ± LY341495 – Figure 2 |
| 2. IP 2-PMPA – Figure 3 |
| 3. IP 2-PMPA – Figure 4 |
| PMPA analgesic in phase 1 and phase 2 flinching response |
| Formalin increases glutamate release in contralateral LC |
| Formalin not increase glutamate release in ipsilateral LC |
| IP 2-PMPA block glutamate release in contralateral LC |
| IP 2-PMPA increases noradrenaline in lumbar CSF with or without formalin |
| IP 2-PMPA reduction of flinching response is blocked by IT Idazoxan |
| IP saline + IT idazoxan significantly increased the phase 1 flinching response but not the phase 2 response relative to IP saline alone. |

| (b) |
| 1. IP 2-PMPA reduces flinching – Figure 5 |
| 2. ZJ43 or 2-PMPA into Contralateral or Ipsilateral LC – Figure 8 |
| 3. ZJ43 or 2-PMPA into Contralateral or Ipsilateral LC – Figure 9 |
| ZJ43 or 2-PMPA into Contralateral or Ipsilateral LC – Figure 10 |
| Contralateral LC CNQX blocks effect of PMPA on flinching |
| Both Contralateral and Ipsilateral injections reduce flinching response |
| Only Contralateral LC drug effect is reversed by IP LY341495 |
| Analgesic effect is dose dependent |
| Contralateral analgesic effect is not blocked by IT Idazoxan |
| Ipsilateral analgesic effect is blocked by IT Idazoxan |
Nonaka et al.

In the formalin test, 50 \( \mu l \) of 5% formalin was injected subcutaneously (SC) into the dorsal surface of the hind paw with a 26-gauge needle under brief halothane anesthesia. Within 1 min after formalin injection, spontaneous flinching of the injected paw could be observed. Flinching was readily discriminated as a rapid and brief withdrawal or flexion of the injected paw. This pain-related behavior was quantified by counting the number of flinches for 1 min periods at 5 min intervals from 0 to 60 min after the injection. Two phases of spontaneous flinching behavior were observed: an initial acute phase (phase 1: during the first 6 min after the formalin injection) and a prolonged tonic phase (phase 2: beginning about 10 min after the formalin injection).

**Formalin test**

In the formalin test, 50 \( \mu l \) of 5% formalin was injected subcutaneously (SC) into the dorsal surface of the hind paw with a 26-gauge needle under brief halothane anesthesia. Within 1 min after formalin injection, spontaneous flinching of the injected paw could be observed. Flinching was readily discriminated as a rapid and brief withdrawal or flexion of the injected paw. This pain-related behavior was quantified by counting the number of flinches for 1 min periods at 5 min intervals from 0 to 60 min after the injection. Two phases of spontaneous flinching behavior were observed: an initial acute phase (phase 1: during the first 6 min after the formalin injection) and a prolonged tonic phase (phase 2: beginning about 10 min after the formalin injection).

**Intrathecal microdialysis and assay of noradrenaline level in the lumbar spinal cord**

Rats were anesthetized with halothane and placed in a stereotaxic apparatus for surgical implantation of a microdialysis probe. The intrathecal microdialysis probe (exposed tip, 10 mm, Cut-off of 50 kDa; EICOM, Japan) was passed caudally 7.5 cm from the cisterna magnum to the lumbar enlargement. After surgery, each rat was individually housed and the probe was perfused at 1 \( \mu l/min \) with artificial cerebrospinal fluid. The rat was allowed to recover for 24 h before footpad formalin injection.

Microdialysis was carried out in conscious and freely moving rats. During the experiment, the probe was perfused at 2 \( \mu l/min \) with artificial cerebrospinal fluid, and dialysate samples were collected every 15 min. Three baseline fractions were collected before the 2-PMPA or saline injection. Fifteen minutes after the pretreatment of 2-PMPA (50 mg/kg IP) or saline, formalin (5%, 50 \( \mu l \)) was injected into the dorsal side of the left hind-paw and dialysate samples were collected during the formalin test. Samples were subsequently analyzed for noradrenaline.

Noradrenaline in the microdialysate samples was analyzed by reverse phase high performance liquid chromatography (HPLC) and electrochemical detection (ECD-300, EICOM, Japan). A reversed-phase column (EICOMPAK, CA-5ODS, 2.1 \( \times \) 150 mm, EICOM) was used and the mobile phase for detection of noradrenaline composed of 0.1 M phosphate buffer solution (PBS) and 50 mg/ml EDTA-2Na with methanol (95:5 v/v) in water adjusted to pH 6.0 with 400 mg/l 1-octanesulfonic acid (sodium salt). The flow rate was 0.23 ml/min (EP-300, EICOM). The column temperature was maintained at 25\( ^\circ \)C and the applied potential was set at +450 mV (ATC-300, EICOM). Quantification was obtained from standard curves.

**LC microdialysis and assay of glutamate level**

Rats were anesthetized with 10% chloral hydrate (0.3 mg/kg) and placed in a stereotaxic apparatus for surgical implantation of a guide cannula. The guide cannula (EICOM) was positioned to the ipsilateral and contralateral LC according to the coordinates (AP: -10.0 mm, H: 6.8 mm, L: 1.4 mm). The guide cannula was secured to the skull with dental cement anchored by two stainless steel screws. After surgery,
each rat was individually housed and allowed to recover for 24 h before microdialysis and footpad injection.

Microdialysis was carried out on conscious and freely moving rats. Rats were lightly anesthetized with isoflurane to facilitate manual insertion of the microdialysis probe into the guide cannula. The stylet in the guide cannula was replaced with the microdialysis probe (exposed tip, 2.0 mm; cut-off of 50 kDa; EICOM). The probe was perfused at 2 μl/min with artificial cerebrospinal fluid. After at least 2 h to reach equilibration, dialysate samples were collected every 15 min. Three baseline fractions were collected before 2-PMPA or saline injection and the average of these values was taken as the “100% of control” value for the glutamate levels for each rat. Pretreatment with 2-PMPA (50 mg/kg IP) or saline occurred 15 min before formalin injection (5%, 50 μl) into the dorsal side of the left hind-paw during microdialysis. At the completion of each experiment, rats were euthanized and brains were removed, fixed in 10% formalin and 30 μm coronal sections prepared to confirm probe placement.

Glutamate in the microdialysate samples was derivatized with o-phthalaldehyde (OPA, Sigma, USA) and analyzed by reverse phase HPLC and electrochemical detection (EICOM). A reversed-phase column (Zorbax, SB-C18, 4.6 x 250 mm, 5 μm, Agilent) was used with a mobile phase for detection of glutamate composed of 0.1 M citric acid-sodium acetate and 0.05 mM EDTA with 12% methanol (v/v) in water adjusted to pH 3.8 and 6% DMSO with 1 mM N-hydroxysuccinimide. Endogenous peroxidase was blocked by 30 min incubation with 30% sucrose containing the LC were incubated with rabbit antibody to dopamine β-hydroxylase (DBH) (1:1000; Merck Millipore, Darmstadt, Germany) diluted with PBS containing 5% normal horse serum and 0.3% Triton X-100 for 24 h at room temperature. The sections were then incubated at room temperature for 3 h with Alexa Fluor 488 donkey anti-rabbit IgG (1:100; Molecular

**Immunohistochemistry and antibodies**

The NAAG-specific antisera were prepared and immunohistochemistry was performed as previously described. Briefly, polyclonal NAAG antisera were purified by negative-affinity adsorption against protein-bound N-acetylaspartate and formalin-fixed rat liver tissue. Rats were transcardially perfused with 6% paraformaldehyde in 0.1 M PBS. The brain was removed immediately, post-fixed overnight at 4°C in the same fixative, and then stored in 30% sucrose in PBS overnight. Coronal sections were cut with a microtome at 50 μm.

**DBH immunohistochemistry**

After immersion in PBS containing 5% normal horse serum and 0.3% Triton X-100 for 1 h, tissue sections containing the LC were incubated with rabbit antibody to dopamine β-hydroxylase (DBH) (1:1000; Merck Millipore, Darmstadt, Germany) diluted with PBS containing 5% normal horse serum and 0.3% Triton X-100 for 24 h at room temperature. The sections were then incubated at room temperature for 3 h with Alexa Fluor 488 donkey anti-rabbit IgG (1:100; Molecular

**Preparation of tissue sections**

The rats were anesthetized deeply with halothane and transcardially perfused with saline to wash blood out of the cerebral vessels, followed by 4% paraformaldehyde in 0.1 M PBS. The brain was removed immediately, post-fixed overnight at 4°C in the same fixative, and then stored in 30% sucrose in PBS overnight. Coronal sections were cut with a microtome at 50 μm.
Probes) in PBS containing 5% normal horse serum and 0.3% Triton X-100 and cover slipped with SlowFade Diamond Antifade mountant (Molecular Probes). Sections were photographed under confocal laser scanning microscopy.

Statistical analysis

The time-response data are presented as the mean flinches (±SEM) per minute for the periods between 1–2 and 5–6 min after formalin treatment and then for 1 min periods at 5 min intervals up to 60 min. The data from phase 1 (0–6 min) and phase 2 (10–60 min) observations were considered separately. In each case, the cumulative instances of formalin-evoked flinches during the phase 1 and phase 2 were calculated for each rat. For the ZJ43 dose response study, one-way analysis of variance (ANOVA) was used with Tukey post-hoc test. The effects of 2-PMPA injected into either contralateral or ipsilateral LC to the formalin injected side were compared with those of saline.

Microdialysis data are expressed as percentage of basal values (calculated as means of the three samples before injections). The basal concentrations of either lumbar enlargement noradrenaline or LC glutamate in the dialysates, uncorrected for recovery, were 0.35 ± 0.25 nM or 1.17 ± 0.18 μM, respectively. The values were expressed as a % of baseline level for each rat and the mean and standard error were determined for each treatment group. All data were given as mean ± standard error of the mean (SEM) and not corrected for “recovery” of the dialysis procedure. Two-factor ANOVA for repeated measurements was used to examine the possibility of significant differences (p < 0.05) between groups followed by a Student’s t-test for every time-point.

Results

NAAG in the LC

In the rat brainstem, immunoreactivity for NAAG in the LC was among the strongest of all neuronal groups (Figure 1(a)). The cell bodies of the principal neurons of the LC express strong NAAG immunoreactivity suggesting that the peptide is coexpressed with noradrenaline in the descending spinal pathway (Figure 1(b)). Additionally, small interneuron-like cells in the LC also express NAAG immunoreactivity, a result that suggests that the peptide might regulate the activity of the principal neurons within the LC.

Analgesic effect of IP-injected 2-PMPA

Consistent with our previous studies,19,22 IP injection of 50 mg/kg 2-PMPA attenuated the formalin-induced agitation behavior as compared with IP saline injected rats (p < 0.01) (Figure 2). The effect of 2-PMPA was blocked by IP injection of 1 mg/kg of the group II mGluR antagonist LY341495 (p < 0.01); 1 mg/kg of LY341495 itself had no significant effect on the formalin-induced agitation behavior.

Inflammation-induced glutamate release in the LC

Formalin injection into the rat footpad stimulated a significant increase in glutamate levels in the contralateral, but not the ipsilateral, LC (p < 0.05 by two-way ANOVA, Figure 3(a)). This increase was substantially reduced by preinjection with 50 mg/kg 2-PMPA (IP) (p < 0.05 by two-way ANOVA, Figure 3(b), same data are plotted for saline contralateral LC in Figure 3(a) and (b)). Since basal and stimulated extracellular levels of glutamate are nearly 10-fold greater than NAAG,3

---

Figure 1. NAAG immunohistochemistry in the rat brainstem. Highly purified antibodies to protein-coupled NAAG show NAAG localization in the brainstem (a). Box in (a) indicates the area of higher magnification in (b). IV: 4th ventricle; LC: locus coeruleus; MeV: mesencephalic nucleus of the trigeminal nerve. Bar: 800 μm (a) and 100 μm (b).
Figure 3. Microdialysis sampling for glutamate release in the LC. Glutamate levels are expressed as a percent of the three baseline samples for each animal. (a) Effect of formalin on glutamate release in ipsilateral and contralateral LC. There was a significant effect on glutamate levels in the 45–90 min dialysate samples. Formalin significantly increased glutamate release in the contralateral LC but not the ipsilateral LC. (b) Effect of 2-PMPA (50 mg/kg, i.p.) or saline on formalin-induced glutamate release in contralateral LC. There was a significant main effect on glutamate levels in the 45–115 min dialysate samples. 2-PMPA significantly decreased formalin-induced glutamate release in the contralateral LC as compared with saline group. The same saline contralateral LC data were used in (a) and (b). (c) Effect of 2-PMPA (50 mg/kg, i.p.) or saline on formalin-induced glutamate release in ipsilateral LC. 2-PMPA had no effect on the release of glutamate in the ipsilateral LC after formalin injection.
this decrease in glutamate levels can be attributed to a decrease in synaptically released glutamate rather than a decrease in glutamate released from NAAG. 2-PMPA (IP) had no significant effect on the basal level of glutamate in the ipsilateral LC ($p > 0.1$, Figure 3(c), same data are plotted for saline ipsilateral LC in Figure 3(a) and (c)).

Inflammation induces release of spinal noradrenaline

Rats injected in the footpad with formalin + IP saline had a greater level of spinal noradrenaline release than rats treated with IP saline but not formalin ($p = 0.006$, Figure 4(a)). Preinjection of 50 mg/kg 2-PMPA (IP) significantly increased the release of noradrenaline that followed formalin treatment ($p < 0.001$). IP 2-PMPA alone also induced a smaller but significant increase in spinal noradrenaline release relative to the IP saline alone treatment ($p < 0.001$).

The analgesic effect of IP 2-PMPA on phase 2, but not phase 1, of the formalin footpad test was antagonized by IT idazoxan (phase 1: $p = 0.73$; phase 2: $p = 0.0002$ by t-test, Figure 4(b)). IT idazoxan with saline had a significant effect on phase 1, but not phase 2 of the formalin-induced agitation behavior induced by paw formalin injection as compared with IP saline injected rats (phase 1: $p = 0.003$; phase 2: $p = 0.112$ by t-test). While these data suggest that spinal noradrenaline mediates the effect of systemic 2-PMPA on the phase 2 response, these data do not permit interpretation of its role in the phase 1 response.

Figure 4. Role of noradrenaline in the lumber CSF during rat formalin test. Upper panel (a) shows the microdialysis data for noradrenaline release into the lumber CSF during formalin test. Either formalin injection itself or 2-PMPA (50 mg/kg, IP) itself enhances noradrenaline release equally. IP injection of 2-PMPA 15 min before the formalin injection-induced significant noradrenaline release as compared with 2-PMPA itself or formalin itself. Samples were collected over 15 min intervals. Ordinate: % of the three baseline samples for each animal; abscissa: time after drug administration (min). Lower panel (b) shows the effect of IT idazoxan (alpha 2-adrenergic receptor antagonist) on the behavioral response to IP 2-PMPA in the rat formalin test. 2-PMPA was injected IP 10 min before the formalin injection. IP saline + IT idazoxan decreased the phase 1 flinching response but not the phase 2 response in the rat formalin test relative to IP saline alone. Ordinate: number of flinches per min; abscissa: time after formalin administration (min).
1 response inasmuch as IT idazoxan itself blocked formalin-induced phase 1 agitation.

2-PMPA-induced analgesia blocked by CNQX

Injection of the AMPA receptor antagonist CNQX into the contralateral LC antagonized the analgesic effect of IP injected 2-PMPA (50 mg/kg, IP) on the phase 2 response ($p < 0.002$) (Figure 5). CNQX into the ipsilateral LC had no significant effect on the formalin-induced agitation behavior as compared with rats with saline injected into LC (phase 1: $p = 0.920$; phase 2: $p = 0.694$; data not shown).

Retrograde tracing from spinal cord to DBH positive neurons in the LC

Fluorospheres injected unilaterally at the T12-L1 level of the spinal cord were observed in DBH positive neurons both ipsilateral and contralateral to the tracer injected side of the spine indicating that spinal nociceptive neurons were innervated by both ipsilateral and contralateral LC neurons (Figure 6).

Analgesic effects of ZJ43 and 2-PMPA injected into LC

Microinjection of the GCPII inhibitor ZJ43 into the LC (Figure 7) either contralateral or ipsilateral to the formalin-injected side significantly decreased the early (phase 1, contralateral: $p < 0.05$; ipsilateral: $p < 0.001$) and late (phase 2, contralateral: $p < 0.005$; ipsilateral: $p < 0.001$) phase responses (Figure 8) in a dose-dependent manner.
When 150 mg of ZJ43 was injected via a guide cannula that was placed 2.0 mm caudal and 1.6 mm lateral (AP: \( \text{C0}_10.0 \) mm, H: 8.0 mm, L: 1.4 mm from Bregma) to the LC cannula (AP: \( \text{C0}_10.0 \) mm, H: 8.0 mm, L: 1.4 mm from Bregma), ZJ43 had no effect on the flinching behavior induced by paw formalin injection as compared with the effect of ZJ43 microinjected via a LC cannula (Figure 8).

150 mg of 2-PMPA injected into LC either contralateral or ipsilateral to the formalin-injected side was antagonized by IP injection of the group II metabotropic glutamate receptor antagonist LY341495 (Contralateral: ZJ43: phase 1: \( p < 0.005 \), phase 2: \( p < 0.005 \); 2-PMPA: phase 1: \( p < 0.01 \), phase 2: \( p < 0.05 \); Ipsilateral: ZJ43: phase 1: \( p > 0.3 \), phase 2: \( p > 0.8 \); 2-PMPA: phase 1: \( p > 0.05 \), phase 2: \( p > 0.4 \), by t-test) (Figure 8).

Spinal (intrathecal, IT) injection of the alpha 2 adrenergic receptor antagonist idazoxan reversed the analgesic effects of ZJ43 and 2-PMPA injected into contralateral LC, but not into ipsilateral LC (Figure 10; Contralateral: ZJ43 vs. ZJ+idazoxan: phase 1: \( p > 0.7 \), phase 2: \( p > 0.4 \); 2-PMPA: phase 1: \( p > 0.4 \), phase 2: \( p > 0.05 \), by t-test). Idazoxan had no significant
Figure 10. Effect of intrathecal (IT, spinal) injection 30 mg of alpha 2-adrenergic receptor antagonist, idazoxan, on the analgesic effects of 150 mg of ZJ43 and 150 mg of 2-PMPA microinjected into either contralateral LC or ipsilateral LC to the formalin injection side. ZJ43 or 2-PMPA or saline were microinjected into LC 10 min before the formalin injection. Each point represents the mean of five rats. ZJ43 reduced phase 1 and phase 2 response in a dose-dependent manner at the dose between 1.5 and 150 mg (by one-way ANOVA). * p < 0.05 by Tukey post-hoc test as compared with the phase 1 or phase 2 responses in the saline treated control rats (open circle).

Figure 9. ZJ43 dose response in the LC. Dose-response curves for ZJ43 injection into the LC either contralateral or ipsilateral to the formalin injection site presenting the cumulative instances of formalin-induced flinching behavior during phase 1 and phase 2 of the formalin test (closed circle). Open circle represents sum of flinches by saline treated rats (control). ZJ43 or saline was microinjected into LC 10 min before the formalin injection. Each point represents the mean of five rats. ZJ43 reduced phase 1 and phase 2 response in a dose-dependent manner at the dose between 1.5 and 150 mg (by one-way ANOVA). * p < 0.05 by Tukey post-hoc test as compared with the phase 1 or phase 2 responses in the saline treated control rats (open circle).
effect on ZJ43 or 2-PMPA injected into the ipsilateral LC.

Discussion

Confirming an earlier study, systemic treatment with a GCPII inhibitor reduces both phases of the response to inflammatory pain in the formalin footpad model. Consistent with the hypothesis that this effect is mediated by an increase in NAAG activation of mGluR3, this effect is blocked by the group II mGluR antagonist LY341495 (Figure 2). Previous microdialysis studies demonstrated that inhibitors of GCPII elevate extracellular NAAG levels and inhibit the release of neurotransmitters, including glutamate and GABA. NAAG and mGluR3 are widely distributed within the pain perception pathway and NAAG peptidase inhibitors introduced centrally into the spinal cord (intrathecal), third ventricle, contralateral periaqueductal gray, and rostral ventromedial medulla and peripherally into the footpad, reduced the first and second phase responses to formalin treatment.

CNQX in the contralateral LC clearly discriminates between the roles of AMPA receptors as mediators of 2-PMPA effects on phase 1 and 2 responses to formalin treatment (Figure 5). The phase 1 response to systemic 2-PMPA seems unaffected by the antagonist in the LC while the phase 2 response is significantly reduced (p < 0.01). While the circuitry mediating the phase 1 response is not clearly resolved, the spinal cord is considered to have a central role. However, GCPII inhibition in other brain areas reduces both phases of the formalin response. More importantly, these data not only demonstrate that the contralateral LC contributes to the analgesic effects of systemic GCPII inhibition but that AMPA receptors in the LC have a role in this process.

Noradrenergic neurons in the LC mediate analgesia via axon terminals in the spinal dorsal horn. Both the left and right LC have a significant influence on unilateral nociception in formalin test in rats, but the contralateral LC is reported to have a lesser effect. In order to determine if this pathway is involved, the mechanism underlying the analgesic effects of systemic treatment with GCPII inhibitors, spinal noradrenaline levels were assessed in the inflammatory pain model. The finding that 2-PMPA increased flux of spinal noradrenaline following induction of inflammatory pain (Figure 4) supports the hypothesis that the LC contributed to the efficacy of the systemically administered peptidase inhibitor. Consistent with this conclusion, the analgesic effect of IP 2-PMPA was blocked by spinal treatment an alpha 2 adrenergic receptor antagonist, idazoxan (Figure 4). To test this directly, the two structurally different inhibitors were injected into the contralateral LC. Both drugs produced a group II mGluR-dependent inhibition of both phases of the response to inflammatory pain (Figures 7 and 8) via a process that was reversed by spinal application of idazoxan, a result that supports a role for alpha 2 adrenergic receptor mediation of the analgesic action of GCPII inhibition (Figure 10).

A caveat to this interpretation of the idazoxan data is the ability of this drug to also act as imidazoline receptor agonist, an activity that could lead to non-competitive inhibition of NMDA receptors. These data demonstrate that inhibitors of NAAG hydrolysis in the contralateral LC mediate analgesia via activation of noradrenergic LC neurons and support the hypothesis that systemic administration of these inhibitors achieves at least one element of their analgesic efficacy via this descending pathway.

The ipsilateral LC is in the primary ascending and the contralateral LC is in the primary descending inhibitory pain pathway. Both innervate the dorsal spinal cord bilaterally (Figure 6) and GCPII inhibition in both LCs produced an analgesic-like effect in response to unilateral footpad inflammation (Figure 8). However, the mechanisms of action of the inhibitors differ between ipsilateral and contralateral LC. Inhibition in the LC contralateral to the formalin-treated footpad was reversed by systemic administration of the group II mGluR antagonist, a result that suggests NAAG activation of mGluR3. Consistent with the model of NAAG activation of presynaptic mGluR3 with consequent reduction in glutamate release, systemic administration of the inhibitor also reduced the inflammation-induced increase in glutamate levels in the contralateral LC. Similar inhibition of treatment-induced increases in transmitter release was obtained in animal models of stroke, traumatic brain injury and schizophrenia. However, given the multiple inputs to and transmitters acting within the LC, it is difficult to model these results in the contralateral LC with decreased glutamate activity inasmuch as microinjection of the AMPA receptor antagonist in the contralateral LC reversed the effect of systemic 2-PMPA (Figure 5). This action of CNQX in the LC is similar to its efficacy in blocking the analgesic efficacy of gabapentin in the formalin inflammatory pain model.

While GCPII inhibition in the ipsilateral LC reduced the response to formalin treatment, this action was not sensitive to the group II antagonist (Figure 8), and thus was not mediated by NAAG activation of mGluR3. These data rule out a direct role for NAAG activation of a group II receptor in the ipsilateral LC in mediating analgesic action of systemically administered inhibitors since the systemic effect of the inhibitors is group II mGluR-dependent. Additionally, the ipsilateral LC differed from the contralateral in that formalin treatment did not elevate glutamate levels and these levels were not
reduced by systemic treatment with 2-PMPA (Figure 3). Given the finding that NAAG also acts as an antagonist at some but not all subtypes of NMDA receptors,\textsuperscript{9,10,11,36} it might be that the reduced flinching response induced by ipsilateral microinjection of ZJ43 and 2-PMPA was mediated by NAAG acting as an antagonist at NMDA receptors in the LC containing 2A and 2B subunits. However, the role of glutamate receptors in the LC is not clear. For example, in a study on the analgesic effects of LC treatment with estradiol in the rat formalin model,\textsuperscript{37} treatment with the NMDA antagonist (APV) and the AMPA antagonist (CNQX) in the ipsilateral LC did not significantly moderate the effect of estradiol on flinching behavior.

However, the failure of spinal administration of the alpha 2 receptor antagonist idazoxan to block the efficacy of ZJ43 and 2-PMPA that were microinjected into the ipsilateral LC (Figure 10) implies that this analgesic action is not the result of activation of noradrenergic neurons in the ipsilateral LC as would be suggested by NAAG antagonism of excitatory receptors in the LC. Inasmuch as the ipsilateral LC also provides an element in a secondary ascending pain projection pathway,\textsuperscript{34} it may be that the efficacy of the GCPII inhibitors in the ipsilateral LC is due to NAAG antagonism of NMDA receptors\textsuperscript{36} in this element of the ascending circuit.

Conclusion
Systemically administered GCPII inhibitors induce analgesia in this inflammatory pain model via a process that is blocked by a group II mGluR antagonist and by microinjection of an AMPA receptor antagonist directly into the contralateral LC. The mechanism underlying analgesia includes reduction of inflammation-induced elevation of glutamate release in the contralateral LC and increased release of noradrenaline at LC synapses in the spinal cord. Direct administration of GCPII inhibitors ZJ42 and 2-PMPA into the LC contralateral to the site of inflammation induced analgesia via a group II mGluR-dependent mechanism. Microinjection of the inhibitors into the ipsilateral LC also reduced the response to inflammation by a process that is not affected by a group II mGluR antagonist and thus is unrelated to group II mGluR activation by NAAG. These data provide additional proof of the concept that GCPII inhibition is a promising, novel treatment for inflammatory pain.

Authors’ contributions
Takahiro Nonaka: Design experimental protocol. Acquire and analyze the data; Toshihiko Yamada: Acquire and analyze the data. Tatsuo Ishimura: Acquire and analyze the data. Daiying Zuo: Acquire and analyze the data. John R Moffett: Acquired and analyzed data. Tatuso Yamamoto: Design experimental protocol and analyze the data. Co-drafted the manuscript. Joseph H Neale consulted on the experimental design and co-drafted the manuscript.

Declaration of Conflicting Interests
The author(s) have no conflicting interests associated with this research.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Tatsuo Yamamoto was supported by the Grant-in-Aid for Scientific Research (C). JHN supported by grants from the NIH and generous gifts from Nancy and Daniel Paduano.

References
1. Neale JH. N-acetylaspartylglutamate is an agonist at mGluR\textsubscript{3} in vivo and in vitro. \textit{J Neurochem} 2011; 119: 891–895.
2. Neale JH, Olszewski RT, Zuo D, et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. \textit{J Neurochem} 2011; 118: 490–498.
3. Zhong C, Zhao X, Van KC, et al. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. \textit{J Neurochem} 2006; 97: 1015–1025.
4. Yamamoto T, Hirasawa S, Wroblewska B, et al. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. \textit{Eur J Neurosci} 2004; 20: 483–494.
5. Zuo D, Bzdega T, Olszewski RT, et al. Effects of NAAG peptidase inhibition on release of glutamate and dopamine in the prefrontal cortex and nucleus accumbens in the phencyclidine model of schizophrenia. \textit{J Biol Chem} 2012; 287: 21773–21782.
6. Slusher BS, Vornov JJ, Thomas AG, et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. \textit{Nat Med} 1999; 5: 1396–1402.
7. Zhao J, Ramadan E, Cappiello M, et al. NAAG inhibits KCl-induced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. \textit{Eur J Neurosci} 2001; 13: 340–346.
8. Sanabria E, Wozniak K, Slusher BS, et al. GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. \textit{J Neurophysiol} 2004; 91: 182–193.
9. Khacho P, Wang B, Ahlskog N, et al. Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit- and pH-dependent in the CA1 region of the mouse hippocampus. \textit{Neurobiol Dis} 2015; 282: 580–592.
10. Losi G, Vicini S and Neale J. NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. \textit{Neuropharmacology} 2004; 46: 490–496.
11. Fricker AC, Mok MH, de la Flor R, et al. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009; 56: 1060–1067.
12. Bacich DJ, Wozniak KM, Lu XC, et al. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem 2005; 95: 314–323.
13. Olszewski RT, Bzdega T and Neale JH. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophr Res 2012; 136: 160–161.
14. Olszewski RT, Janczura KJ, Ball SR, et al. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Transl Psychiatry 2012; 2: e145.
15. Gao Y, Xu S, Cui Z, et al. Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury. J Neurochem 2015; 134: 340–353.
16. Cao Y, Gao Y, Xu S, et al. Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury. BMC Neurosci 2016; 17: 15.
17. Yamamoto T, Nozaki-Taguchi N, Sakashita Y, et al. Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 2001; 909: 138–144.
18. Yamamoto T, Nozaki-Taguchi N, Sakashita Y, et al. Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001; 102: 473–479.
19. Yamamoto T, Kozikowski A, Zhou J, et al. Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain 2008; 4: 31.
20. Saito O, Aoe T, Kozikowski A, et al. Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in the bone cancer pain. Can J Anesth 2006; 53: 891–898.
21. Ossipov MH, Dussor GO and Porecca F. Central modulation of pain. J Clin Invest 2010; 120: 3779–3787.
22. Yamada T, Zhu D, Yamamoto T, et al. NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Mol Pain 2012; 8: 67.
23. Ohishi H, Shimemoto R, Nakanishi S, et al. Distribution of the mRNA for a metabolotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 1993; 335: 252–266.
24. Slusher BS, Tsai G, Yoo G, et al. Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated α-linked acidic dipeptidase (NAALADase). J Comp Neurol 1992; 315: 217–229.
25. Fuhrman S, Pulkovits M, Cassidy M, et al. The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J Neurochem 1994; 62: 275–281.
26. Hayashida K, Obata H, Nakajima K, et al. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology 2008; 109: 1077–1084.
27. Kimura M, Suto T, Morado-Urbina CE, et al. Impaired pain-evoked analgesia after nerve injury in rats reflects altered glutamate regulation in the locus coeruleus. Anesthesiology 2015; 123: 899–908.
28. Kozikowski AP, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004; 47: 1729–1738.
29. Tsukamoto T, Wozniak KM and Slusher BS. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007; 12: 767–776.
30. Monn JA, Valli MJ, Massie SM, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999; 42: 1027–1040.
31. Moffett JR and Namboodiri MA. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol 1995; 24: 409–433.
32. Moffett JR, Namboodiri MA and Neale JH. Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 1993; 41: 559–570.
33. Llorca-Torralba M, Borges G, Neto F, et al. Noradrenergic Locus Coeruleus pathways in pain modulation. Neuroscience Epub ahead of print 4 June 2016. DOI: 10.1016/j.neuroscience.2016.05.057.
34. Milhau D, Fagni L, Bockaert J, et al. Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. Neuropharmacology 2000; 39: 2244–2254.
35. Neale JH, Olszewski RT, Gehl LM, et al. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 2005; 26: 477–484.
36. Khacho P and Wang Bergeron R. The good and bad sides of NAA. Advances in Pharm 2016; 79: 311–349.
37. Khakpay R, Semnann S, Javan M, et al. The effect of intra-lumbar coeruleus injection of 17beta-estradiol on inflammatory pain modulation in male rat. Behav Brain Res 2010; 214: 409–416.